About Isofol

Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company’s drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world’s third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with a new dosing regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

Read more >>

Upcoming Events

  • May 13, 2025 - May 16, 2025
    CEO interview in connection with the announcement of the rights issue
    In connection with Isofol's decision to new rights issue, CEO Petter Segelman Lindqvist will make a CEO speech that will be published on the website on Tuesday.
  • May 20, 2025 - May 21, 2025
    The Global Forum 2025, Sweden
    Isofol is participating in the Global Forum 2025 in Lund, which is organized by BioStock. On May 20 at 4:00 PM, CEO Petter Segelman Lindqvist will present the company.
  • May 21, 2025 - May 21, 2025
    Interim report January-March 2025

INVESTORS – latest reports and presentations

FOLLOW US

Stay updated on the latest news by
following Isofol on Linkedin.

LinkedIn logotype
Scroll to Top